Clinical Trial

"Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Drug B10-FC After Single Administration to Adult Patients".

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 5, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
A two-stage open-label, prospective, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity study with participation of healthy volunteers in three dose-escalation groups and patients with a confirmed diagnosis of COVID-19.
Trial Details
NCT Number NCT07156864
Lead Sponsor Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Conditions COVID-19
Enrollment 35 participants
Start Date 2025-09
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-05